Pressemeddelelse17.03.2025, 12.05BioStock: Last trading day for Abliva - the company leaves Nasdaq Stockholm
Selskabsmeddelelse03.03.2025, 13.10Delisting of the shares of Abliva: last day of trading 17 March 2025
Selskabsmeddelelse25.02.2025, 09.50Abliva applies for delisting and will convene an extraordinary general meeting
Selskabsmeddelelse15.12.2024, 20.00Statement by the Board of Directors of Abliva regarding the public cash offer from Pharming
Pressemeddelelse09.12.2024, 08.32Abliva Announces Publication of Results from Phase 1a/b Study of KL1333 in the Scientific Journal Brain
Pressemeddelelse04.11.2024, 11.00Abliva will present at the BioStock Life Science Summit, November 21
Pressemeddelelse16.09.2024, 08.30Join Abliva for World Mitochondrial Disease Week 2024, September 16 – 22
Pressemeddelelse26.08.2024, 08.46BioStock: Abliva's CEO - We are the leading programme in mitochondrial disease
Selskabsmeddelelse19.07.2024, 08.30Positive interim analysis in Abliva's FALCON study triggers convertible loan conversion
Selskabsmeddelelse18.07.2024, 22.22Abliva Announces Positive Interim Analysis of the FALCON Study for KL1333 in Primary Mitochondrial Disease